Furthermore, YHJD can inhibit liver metastasis of colorectal cancer (CRC) in vivo, and its therapeutic effect is closely related to the regulation of multiple targets and effector processes, especially the PI3K-AKT signaling pathway and the immune response dominated by natural killer (NK) cells 25. The gene discussed is AKT1; the disease is colorectal carcinoma.